EPISODE · Apr 23, 2025 · 19 MIN
Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape
from PharmaTalkRadio · host Conference Forum
Summary:This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.More specifically: Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGFInsights into how these developments could influence industry trends and investor sentimentForward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapiesIn this podcast:Roy Baynes, MD, PhD, EVP & CMO at Eikon TherapeuticsAsthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst at Truist SecuritiesFor more information, go to IO360summit.com
What this episode covers
Summary:This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.More specifically: Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGFInsights into how these developments could influence industry trends and investor sentimentForward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapiesIn this podcast:Roy Baynes, MD, PhD, EVP & CMO at Eikon TherapeuticsAsthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst at Truist SecuritiesFor more information, go to IO360summit.com
NOW PLAYING
Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.